For the quarter ended September 2025, Charles River Laboratories (CRL) reported revenue of $1 billion, down 0.5% over the same period last year. EPS came in at $2.43, compared to $2.59 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $984.58 million, representing a surprise of +2.06%. The company delivered an EPS surprise of +4.74%, with the consensus EPS estimate being $2.32.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Charles River performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Research Models and Services: $213.47 million versus the three-analyst average estimate of $207.57 million. The reported number represents a year-over-year change of +7.9%.
- Revenue- Manufacturing Solutions: $190.69 million versus the three-analyst average estimate of $190.96 million. The reported number represents a year-over-year change of -3.1%.
- Revenue- Discovery and Safety Assessment: $600.69 million compared to the $582.22 million average estimate based on three analysts. The reported number represents a change of -2.3% year over year.
- Operating income- Research Models and Services- Non-GAAP: $53.28 million compared to the $44.93 million average estimate based on three analysts.
- Operating income- Discovery and Safety Assessment- Non-GAAP: $152.53 million compared to the $138.22 million average estimate based on three analysts.
- Operating income- Manufacturing Solutions- Non-GAAP: $50.83 million versus $48.82 million estimated by three analysts on average.
- Operating income- Unallocated Corporate Overhead: $-63.83 million versus the three-analyst average estimate of $-61.19 million.
- Operating income- Research Models and Services: $34.55 million compared to the $34.09 million average estimate based on two analysts.
- Operating income- Discovery and Safety Assessment: $123.15 million versus the two-analyst average estimate of $109.46 million.
- Operating income- Manufacturing Solutions: $39.93 million versus the two-analyst average estimate of $22.19 million.
View all Key Company Metrics for Charles River here>>>
Shares of Charles River have returned +4.6% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Charles River Laboratories International, Inc. (CRL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
